Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD | Market Cap | 34.30M +16.9% |
| Revenue (ttm) | 18.52M -23.0% |
| Net Income | -6.97M |
| EPS | -2.74 |
| Shares Out | 2.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 1,462 |
| Open | 12.40 |
| Previous Close | n/a |
| Day's Range | 12.40 - 12.40 |
| 52-Week Range | 5.10 - 15.00 |
| Beta | 1.47 |
| RSI | 50.98 |
| Earnings Date | Mar 27, 2026 |
About Devonian Health Group
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatm... [Read more]
Financial Performance
In fiscal year 2025, Devonian Health Group's revenue was 23.59 million, an increase of 22.19% compared to the previous year's 19.31 million. Losses were -6.01 million, 229.1% more than in 2024.
Financial StatementsNews
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Th...
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
QUEBEC, Feb. 17, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced that a proprietary Thykamine™ fingerprint has been formally filed...
Devonian reports additional molecular data from MASH liver study
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire...
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to t...
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
QUÉBEC, Feb. 2, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinf...
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
QUÉBEC, Jan. 20, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that, in connection with an evaluation of an additional ...
Devonian Health Group Announces Grant of Stock Options
QUEBEC , Dec. 19, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical Company specializing in the development of prescription d...
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
QUÉBEC, Dec. 4, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescrip...
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Fourth quarter distribution revenues of $1.3 million Fourth quarter net loss of $0.4 million, $0.003 per share Annual distribution revenues of $23.6 million Annual net loss of $6 million, $0.041 per s...
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ QUEBEC , Oct. 22, 2025 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Corporation") (...
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Announces Closing of a Private Placement of Units
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Health Group Reports Third Quarter 2025 Financial Results
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its third quarter ended on April 30, 2025. Manag...
Devonian Appoints New Officers and Announces Grant of Stock Options
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announced that the TSX Venture Exchange (the “Exchange”) has approved its application ...
Devonian Health Group Reports Cease Trade Order
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), announces that the Autorité des Marchés Financiers (the “AMF”) has issued a failure to...
Devonian Reports Delay of Financial Reporting
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory di...
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory di...
Devonian Announces the Filing of a New Provisional Patent Application Relating to the Use of Thykamine™ for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory di...
Devonian Reports Positive Results in MASH Liver Study
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory di...
Devonian Reports Distribution Agreement Termination
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Health Group Inc. Reports Superior Anti-Inflammatory Potency of Thykamine™ in Comparative In Vitro Study
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...
Devonian Appoints Viktoria Krasteva as Chief Financial Officer
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammator...